Payment overview · 2025
General Payments
$271.83
14 reported records · 5 companies
Healthcare provider profile · identity verified
Reza Mojtabavi, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAS VEGAS, NV · NPI 1225152598
Verified facts
What the public records show
CMS Open Payments records show Reza Mojtabavi, MD received $271.83 in general payments during 2025 across 14 reported records.
Amgen Inc. accounted for 38.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $104.67 | 38.5% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $89.92 | 33.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.91 | 14.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.76 | 7.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.57 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $271.83 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $104.67 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $104.67 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $74.40 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $31.10 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 35 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 342 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 314 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 221 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 201 | 88 |
| Losartan Potassium | Losartan Potassium | 174 | 63 |
| Metformin Hcl | Metformin Hcl | 160 | 53 |
| Montelukast Sodium | Montelukast Sodium | 153 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 48 |
| Gabapentin | Gabapentin | 128 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 50 |
| Carvedilol | Carvedilol | 121 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 106 | 42 |
| Furosemide | Furosemide | 102 | 70 |
| Allopurinol | Allopurinol | 96 | 35 |
| Lisinopril | Lisinopril | 86 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 49 |
| Eliquis | Apixaban | 83 | 48 |
| Prednisone | Prednisone | 78 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 67 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 29 |
| Potassium Chloride | Potassium Chloride | 56 | 32 |
| Sertraline Hcl | Sertraline Hcl | 56 | 18 |
| Trazodone Hcl | Trazodone Hcl | 55 | 22 |
| Alendronate Sodium | Alendronate Sodium | 53 | 15 |
| Cefdinir | Cefdinir | 52 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 24 |
| Baclofen | Baclofen | 49 | 30 |
| Metformin Hcl Er | Metformin Hcl | 48 | 19 |
| Omeprazole | Omeprazole | 45 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 36 |
| Finasteride | Finasteride | 39 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 16 |
| Minoxidil | Minoxidil | 36 | 14 |
| Ozempic | Semaglutide | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 12 |
| Jardiance | Empagliflozin | 35 | 19 |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Valsartan | Valsartan | 35 | 15 |
| Levofloxacin | Levofloxacin | 34 | 29 |
| Methylprednisolone | Methylprednisolone | 34 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 33 | 18 |
| Spironolactone | Spironolactone | 33 | 15 |
| Glimepiride | Glimepiride | 32 | 13 |
| Sucralfate | Sucralfate | 32 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | 17 |
| Entresto | Sacubitril/Valsartan | 31 | 13 |
| Tradjenta | Linagliptin | 31 | suppressed |
| Linzess | Linaclotide | 30 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | 19 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 21 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 12 |
| Azithromycin | Azithromycin | 23 | 23 |
| Atenolol | Atenolol | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 12 |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Famotidine | Famotidine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 15 |
| Cholestyramine Light | Cholestyramine | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | 13 |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $271.83 · 14 records | Amgen Inc. | AIRSUPRA, BREZTRI, JARDIANCE, MOUNJARO, OTEZLA, REPATHA, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error